XML 145 R74.htm IDEA: XBRL DOCUMENT
v3.22.2.2

LICENSE AGREEMENTS - Narrative (Details) |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Aug. 05, 2021 USD ($) | Nov. 30, 2020 USD ($) | Jul. 30, 2020 USD ($) | Jan. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2016 USD ($) | Aug. 31, 2016 USD ($) | Jun. 30, 2016 USD ($) period | Jun. 30, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2021 EUR (€) | Sep. 30, 2021 USD ($) | Jun. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) | Mar. 31, 2021 EUR (€) | Dec. 31, 2020 USD ($) | Dec. 31, 2020 EUR (€) | Sep. 30, 2020 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2022 EUR (€) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($)
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License and related revenue |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  | $ 2,234,000 |  |  |  |  |  | $ 0 |  | $ 6,544,000 | $ 26,544,000 |  | $ 11,236,000 | $ 0
License agreement, royalty rate |  |  |  |  | 2.00% |  |  |  |  | 2.00% | 2.00% |  |  |  |  |  |  |  |  | 2.00% |  |  | 2.00% |  |  |
Transaction price |  |  |  |  |  | $ 11,200,000 |  |  |  |  |  |  |  |  |  |  | $ 11,200,000 |  | $ 11,200,000 |  |  |  |  |  | 11,200,000 |
Qilu Pharmaceutical Co., Ltd. | Licensing Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 23,000,000 |  |  |  |  |  |  |  |  |  |  |
License and related revenue |  |  |  |  |  | $ 11,200,000 |  |  |  |  |  |  |  | $ 900,000 | 2,800,000 |  |  |  | $ 11,200,000 |  |  |  |  |  |  |
Upfront payment |  |  | $ 12,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,000,000 |
Total milestone payments |  |  | $ 23,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payment, percentage |  |  | 12.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,000,000 |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement, revenue based on development milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  | $ 72,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
University of Zurich |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payment obligation, percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4.00% | 4.00% |  | 4.00% | 4.00% |  |
Third party maximum ownership, percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.00% | 10.00% |  | 10.00% | 10.00% |  |
Third party minimum ownership, percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.00% | 2.00% |  | 2.00% | 2.00% |  |
Expenses related to achievement of development milestone |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000 |  |  |  | 300,000 |  |  |  |  |  | $ 500,000 |  | 300,000 |
University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000 |  |  | $ 500,000 |  |  |
Micromet AG |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payment obligation, percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.50% | 3.50% |  | 3.50% | 3.50% |  |
Expenses related to achievement of development milestone |  |  |  |  |  |  |  |  |  |  | $ 900,000 | € 700,000 |  |  | 600,000 | € 500,000 | 900,000 | € 700,000 |  |  |  |  |  |  |  |
Potential milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,500,000 | € 2,400,000 |  | $ 2,700,000 | € 2,400,000 |  |
License agreement, royalty payment, reduction, conditions not met |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.50% | 1.50% |  | 1.50% | 1.50% |  |
License maintenance fees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 52,148 | € 50,000 |  | $ 56,625 | € 50,000 |  |
XOMA Ireland Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 250,000 |  |  | $ 250,000 |  |  |
Royalty payment obligation, percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.50% | 2.50% |  | 2.50% | 2.50% |  |
Third party maximum ownership, percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% | 50.00% |  | 50.00% | 50.00% |  |
Third party minimum ownership, percent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.75% | 1.75% |  | 1.75% | 1.75% |  |
Roche |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, up-front fee |  |  |  |  |  |  |  | 7,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, additional up-front fee |  |  |  |  |  |  |  | 262,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone achieved |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  | 20,000,000.0 |  |  |  |  |  |  |  |  |  |  |  | $ 20,000,000.0 |  |  |
Payment terms |  |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, option periods | period |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, buyout amount under first option period |  |  |  |  |  |  |  |  | $ 135,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, period to pay buyout option once exercised |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, buyout amount under second option period |  |  |  |  |  |  |  |  | $ 265,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Buyout amount under second option period |  |  |  |  |  |  |  |  | $ 220,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Roche | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from milestone achieved |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Roche | EBI-031 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone achieved |  |  |  |  | $ 20,000,000 |  |  |  |  | $ 20,000,000 | 20,000,000 |  |  |  |  |  |  |  |  | $ 20,000,000 |  |  | $ 20,000,000 |  |  |
Payment terms |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 days | 30 days |  | 30 days | 30 days |  |
License and related revenue |  |  |  |  |  |  | $ 20,000,000 |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from milestone achieved |  |  |  | 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Roche | EBI-031 | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, royalty rate |  |  |  |  | 7.50% |  |  |  |  | 7.50% | 7.50% |  |  |  |  |  |  |  |  | 7.50% |  |  | 7.50% |  |  |
Roche | EBI-031 | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, royalty rate |  |  |  |  | 15.00% |  |  |  |  | 15.00% | 15.00% |  |  |  |  |  |  |  |  | 15.00% |  |  | 15.00% |  |  |
Roche | EBI-031 | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from milestone achieved |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Roche | IL-6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, royalty rate |  |  |  |  | 50.00% |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |
Roche | First Indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  | 197,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Roche | Collaborative arrangement, revenue based on development milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  | 72,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Roche | Collaborative arrangement, revenue based on development milestone | EBI-031 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  | $ 22,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Roche | Collaborative Arrangement, Revenue Based on Development Milestone, Phase II |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  | 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Roche | Collaborative arrangement, revenue based on regulatory milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  | 50,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Roche | Collaborative arrangement, revenue based on commercialization milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  | 75,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Roche | Second Indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, amount payable upon achievement of specified milestone |  |  |  |  |  |  |  | $ 65,000,000 |  |  |  |  |  |  |  |  |  |  |  | $ 65,000,000 |  |  |  |  |  |
MENA License Agreement | Licensing Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License and related revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,500,000 |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  |  | $ 1,500,000 |  |  |  |  |  | $ 1,500,000 |  |  |  |  |  | $ 1,500,000 |  |  |  |  |  | $ 1,500,000 |  | $ 1,500,000 |
Royalty revenue, percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50 |  |  |  |  |  |  |  | 50 |
Eczacibasi Pharmaceuticals Marketing Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments | $ 2,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price | $ 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Eczacibasi Pharmaceuticals Marketing Agreement | TURKEY |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Organization And Basis Of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty revenue, percentage | 30 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Accounts Receivable, Payment Terms + References No definition available. + Details
Name: | sesn_AccountsReceivablePaymentTerms
Namespace Prefix: | sesn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Long-term Purchase Commitment, Milestone Amount + References No definition available. + Details
Name: | sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Milestone Payments + References No definition available. + Details
Name: | sesn_BusinessCombinationMilestonePayments
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Royalty Payment Percent + References No definition available. + Details
Name: | sesn_BusinessCombinationRoyaltyPaymentPercent
Namespace Prefix: | sesn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Additional Up-Front Fee + References No definition available. + Details
Name: | sesn_LicenseAgreementAdditionalUpFrontFee
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Amount Payable Upon Achievement of Specified Milestone + References No definition available. + Details
Name: | sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Buyout Amount Under First Option Period + References No definition available. + Details
Name: | sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Buyout Amount Under Second Option Period + References No definition available. + Details
Name: | sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product + References No definition available. + Details
Name: | sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Agreement, Milestone Achieved + References No definition available. + Details
Name: | sesn_LicenseAgreementMilestoneAchieved
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License Agreement, Milestone Achievement Expense + References No definition available. + Details
Name: | sesn_LicenseAgreementMilestoneAchievementExpense
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Agreement, Option Periods + References No definition available. + Details
Name: | sesn_LicenseAgreementOptionPeriods
Namespace Prefix: | sesn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Percentage of Royalty On Net Product Sales + References No definition available. + Details
Name: | sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales
Namespace Prefix: | sesn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Percentage of Royalty on Net Product Sales, Minimum + References No definition available. + Details
Name: | sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
Namespace Prefix: | sesn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed + References No definition available. + Details
Name: | sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
Namespace Prefix: | sesn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Period to Pay Buyout Option Once Exercised + References No definition available. + Details
Name: | sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised
Namespace Prefix: | sesn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Proceeds From Milestone Achieved + References No definition available. + Details
Name: | sesn_LicenseAgreementProceedsFromMilestoneAchieved
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent + References No definition available. + Details
Name: | sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent
Namespace Prefix: | sesn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Royalty Rate + References No definition available. + Details
Name: | sesn_LicenseAgreementRoyaltyRate
Namespace Prefix: | sesn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition License Agreement, Up-front Fee + References No definition available. + Details
Name: | sesn_LicenseAgreementUpfrontFee
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License Maintenance Fees + References No definition available. + Details
Name: | sesn_LicenseMaintenanceFees
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Organization And Basis Of Presentation [Line Items] + References No definition available. + Details
Name: | sesn_OrganizationAndBasisOfPresentationLineItems
Namespace Prefix: | sesn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Milestone Method, Potential Milestone Payments + References No definition available. + Details
Name: | sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments
Namespace Prefix: | sesn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty Revenue, Percentage + References No definition available. + Details
Name: | sesn_RoyaltyRevenuePercentage
Namespace Prefix: | sesn_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_MicrometAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sesn_EBI031Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sesn_IL6Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sesn_FirstIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sesn_SecondIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_TR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |